

RECORDATI: PUBLICATION OF LISTS OF CANDIDATES FOR THE APPOINTMENT OF DIRECTOR AND STATUTORY AUDITOR OF THE COMPANY

Milan, 27 March 2014 – Pursuant to art. 144-octies, paragraph 1 of Consob's Regulation 11971/1999 ("Issuers' Regulations") and with reference to the Shareholders Ordinary General Meeting to be held on 17th April 2014 in a single call, RECORDATI S.p.A. informs that the following documents are available to the public at the Company's registered offices, at Borsa Italiana S.p.A. and on the company's website www.recordati.it (section Investors/Shareholders Meetings/2014):

- the lists for the appointment of the Directors and of the Statutory Auditors filed by the majority shareholder, Fimeì Finanziaria Mobiliare ed Immobiliare S.p.A., which owns 51.644% of RECORDATI S.p.A.'s share capital;
- the list for the appointment of the Directors, including only one candidate, filed by the shareholder TORRE Società Semplice, which owns about 3.20% of RECORDATI S.p.A.'s share capital.

Please note that the above mentioned lists are available jointly with the relevant documentation requested by law and by the Company's By-laws.

Recordati, established in 1926, is an international pharmaceutical group, listed on the Italian Stock Exchange (Reuters RECI.MI, Bloomberg REC IM, ISIN IT 0003828271), with a total staff of around 4,000, dedicated to the research, development, manufacturing and marketing of pharmaceuticals. Headquartered in Milan, Italy, Recordati has operations in the main European countries, in Russia, in other Central and Eastern European countries, in Turkey, in North Africa and in the United States of America. An efficient field force of medical representatives promotes a wide range of innovative pharmaceuticals, both proprietary and under license, in a number of therapeutic areas including a specialized business dedicated to treatments for rare diseases. Recordati is a partner of choice for new product licenses for its territories. Recordati is committed to the research and development of new specialties within the urogenital therapeutic area and of treatments for rare diseases. Consolidated revenue for 2013 was € 941.6 million, operating income was € 195.4 million and net income was € 133.7 million.

For further information:

Recordati website: www.recordati.com

Investor Relations

Marianne Tatschke
(39)0248787393
e-mail: inver@recordati.it

Media Relations

Ketchum
Cristina Risciotti, (39)0262411919, cristina.risciotti@ketchum.com
Marzia Ongaretti, (39)0262411915, marzia.ongaretti@ketchum.com

Statements contained in this release, other than historical facts, are "forward-looking statements" (as such term is defined in the Private Securities Litigation Reform Act of 1995). These statements are based on currently available information, on current best estimates, and on assumptions believed to be reasonable. This information, these estimates and assumptions may prove to be incomplete or erroneous, and involve numerous risks and uncertainties, beyond the Company's control. Hence, actual results may differ materially from those expressed or implied by such forward-looking statements. All mentions and descriptions of Recordati products are intended solely as information on the general nature of the company's activities and are not intended to indicate the advisability of administering any product in any particular instance.

RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.A.

Sede Legale
VIA M. CIVITALI, 1
20148 MILANO, ITALIA
TEL. (39) 0248787.1
FAX (39) 0240073747

CAPITALE SOCIALE € 26.140.644,50 I.V.
REG. IMP. MILANO N. 00748210150
CODICE FISCALE/P.IVA 007482210150
R.E.A. MILANO N. 401832